Therapeutic prospects for paucibacillary leprosy.
Katoch
K
K
Central JALMA Institute for Leprosy (ICMR), Taj Ganj, Agra. rohinik@ndl.vsnl.net.in
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003622:Dapsone / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007917:Leprostatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015439:Leprosy, Borderline / Q000188:drug therapy*; D015441:Leprosy, Tuberculoid / Q000188:drug therapy*; D008911:Minocycline / Q000627:therapeutic use; D015242:Ofloxacin / Q000627:therapeutic use; D019338:Polypharmacy; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D007917:Leprostatic Agents; D003622:Dapsone; D015242:Ofloxacin; D008911:Minocycline; D012293:Rifampin